Kornimate/medical-research-clean huggingface dataset:
phase 3 study of bavituximab plus docetaxel versus docetaxel alone in patients with late-stage non-squamous non-small-cell lung cancer

Conditions: Non-Small-Cell Lung Cancer Stage IIIB; Non-Small-Cell Lung Cancer Stage IV; Non-Small-Cell Lung Cancer Metastatic; Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Non-Small-Cell Lung Carcinoma; Nonsmall Cell Lung Cancer

Summary: the primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.


Eligibility criteria:
key inclusion criteria: * male or female at least 18 years of age * histologically or cytologically confirmed and documented stage iiib/iv non-squamous nsclc according to the american joint committee on cancer staging manual (7th edition) * radiographic disease recurrence or progression during or after front-line platinum-based doublet chemotherapy. for patients with known epidermal growth factor receptor (egfr) activating mutations or anaplastic lymphoma kinase (alk) translocations, appropriate targeted treatment should have been used. mutation testing is not required. * eastern cooperative oncology group (ecog) performance status of 0 or 1 * adequate hematologic, renal and hepatic function exclusion criteria: * squamous, small cell, carcinoid, adenosquamous, large-cell neuroendocrine, or mixed histology containing small-cell or squamous-cell nsclc * known history of bleeding disorders, eg, von willebrand disease or hemophilia * cavitary tumors or tumors invading or abutting large blood vessels * clinically significant bleeding such as gross hematuria, gi bleeding, and hemoptysis within the 6 months before screening * thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, arterial thrombosis) within 6 months of screening * grade 2 or higher peripheral neuropathy

Keywords: sunrise pphm 1202 bavituximab peregrine
prediction of myocardial injury after laparoscopic pheochromocytoma/paraganglioma resection

Conditions: PGL

Summary: this observational study was conducted in patients undergoing elective laparoscopic pheochromocytoma/paraganglioma(ppgl) resection. it mainly answers the following two main questions: 1. what are the risk factors for myocardial injury after laparoscopic ppgl resection？ 2. how to establish the myocardial injury prediction model of laparoscopic ppgl resection? participants were not required to perform additional research work other than the usual postoperative follow-up within 30 days after surgery. no control group was set in this study, and no additional clinical intervention was performed.

mi-ppgl is a single-center observational ambispective cohort study.on the basis of retrospective study, the research team plans to build a structured database to investigate the incidence of myocardial injury in laparoscopic ppgl-resection, and further analyze myocardial injury related risk factors. in particular, timing data such as vital signs(blood pressure,heart rate)will be included to construct an efficient and robust myocardial injury prediction model. at the same time, a prospective cohort study is carried out to verify the model, so as to test the prediction ability of myocardial injury and reduce the incidence of myocardial injury. the investigators expect to enroll 700 patients, including at least 550 patients retrospectively and 150 patients prospectively.in this study, the main endpoint events of the prediction model are binary outcome. conservatively estimated according to the "10epv" principle, that is, each predictive factor included in the model needs at least 10 positive outcome endpoint for estimation (10 events per variable). the investigators expected 5 to 8 predictors to be included in the model, and at least 80 positive events to be included. the incidence of perioperative myocardial injury is 12\~20%, so the estimated sample size was at least 666 patients. considering the absence of data or subject withdrawal from the study. so the investigators expected to include 700 patients, including at least 550 retrospectively and 150 prospectively. stata (version 15.0; stata corp., tx, usa) and r 3.6.1 software (r foundation for statistical computing, vienna, austria) will be used for statistical analysis. binary logistic regression was used to screen risk factors and stratify risk levels. p\ 0.05 was the acceptable level of estimated fitting of the model. decision curve analysis (dca curve) was used to verify the clinical applicability.

Eligibility criteria:
inclusion criteria: * scheduled for laparoscopic ppgl resection exclusion criteria: 1. open or laparoscopic conversion to open ppgl resection was excluded 2. cardiac paraganglioma was excluded 3. history of congenital heart disease or cardiac surgery was excluded 4. patients with preoperative troponin/hypersensitive troponin elevation were excluded 5. carotid body tumor and accessory ganglioma of jugular tympanum without endocrine function were excluded

Keywords: myocardial injury prediciton pheochromocytoma/paraganglioma
ranibizumab supplementing panretinal photocoagulation as treatment for iris/angle neovascularization in retinal ischemic disease

Conditions: Retinal Ischemia

Summary: the object of the study is to compare treatment of iris/angle neovascularization with panretinal photocoagulation (laser) to treatment with panretinal photocoagulation and an anti-angiogenic drug: ranibizumab.

a.to obtain preliminary data on the safety and tolerability of ranibizumab (0.5 mg)in patients with new or progressive neovascularization of the iris or angle due to retinal ischemic diseases in addition to treatment with prp using the incidence and severity of adverse events identified by subjenc reporting vital signs, and ocular examition. b.to assess the proportion of patients who fail to experience regression of iris and angle neovascularization documented by the clinical examination, iris florescein angiography and gonioscopic evaluation.

Eligibility criteria:
inclusion criteria: all subjects must meet the following criteria to be eligible for study entry: 1. signed informed consent and authorization of use and disclosure of protected health information 2. age = 18 years 3. presence of iris neovascularization and or angle neovascularization due to any retinal ischemic disease that is new onset or noted to progress recently on the slit lamp examination or gonioscopy 4. best corrected visual acuity in the study eye 20/20 (snellen equivalent using edtrs protocol at 4 meters) to light perception. only one eye will be enrolled in the study. if both eyes are eligible, the investigator will select the eye to be enrolled. visual acuity in the non-study eye must be better than no light perception 5. patient is able and willing to return for all scheduled visits exclusion criteria: 1. use of intraocular or periocular injection of steroids (for, example triamcinolone) in the study eye within 3 months of the study 2. use of intraocular injection of anti-angiogenic drugs in the study eye and or participation in a clinical trial using an antiangiogenic treatment within 45 days from the enrollment in the study. 3. acute endophthalmitis within 1 month. 4. recent rhegmatogenous retinal detachment or macular hole surgery within last 2 months 5. uncontrolled uveitis in the last month. 6. treatment with prp within 2 weeks of the study enrollment.

Keywords: retinal ischemia: iris/angle neovascularization
the effectiveness of integrated interactive digital health application and telemonitoring in patients with heart failure and reduced ejection fraction

Conditions: Heart Failure; Health Behavior

Summary: patient source: patients discharged from the cardiology ward with heart failure. intervention group: prior to discharge, patients will be provided with and instructed on how to use the "intelligent interactive personal management system for heart failure" as well as a "bluetooth-enabled blood pressure monitor and scale for remote data transmission." control group: patients will receive standard medical care. assessment method: the health-related quality of life questionnaire (eq-5d), kansas city cardiomyopathy questionnaire (kccq-12), and functional assessment of chronic illness therapy - spiritual well-being; the 12-item spiritual well-being scale (facit-sp-12) will be completed before discharge, and at 1 month, 6 months, and 12 months post-discharge. the average time to complete the questionnaires is 10-15 minutes. additionally, cardiovascular events and readmission rates will be tracked and analyzed over a 1-year period.


Eligibility criteria:
inclusion criteria: diagnosed with heart failure exclusion criteria: inability to independently stand or get out of bed. unstable condition

Keywords: heart failure interactive digital health application
safety and efficacy of furestem-ad inj. in patients with moderate to severe chronic atopic dermatitis(ad)

Conditions: Atopic Dermatitis

Summary: this is multi-center, randomized, double-blind, parallel, placebo-controlled phase iii clinical trial to evaluate the efficacy and safety of furestem-ad inj. for moderate to severe chronic atopic dermatitis


Eligibility criteria:
inclusion criteria: 1. of either gender, aged \>=19 2. atopic dermatitis subjects who are coincident with hanifin and rajka diagnosis criteria 3. chronic atopic dermatitis that has been present for at least 3 years 4. easi\>=12 at screening and baseline visit 5. iga\>=3, scorad index\>=25, bsa \>=10% of ad involvement at screegning and baseline visit 6. subjects with documented record of inadequate response to the stable use of topical atopic dermatitis treatment within 24 weeks before participating in the study, or whom are inadvisable due to safety risks 7. subjects who understand and voluntarily sign an informed consent form exclusion criteria: 1. subjects with medical history or surgery/procedure history 2. subjects with diseases at the time of participation in this study (systemic infection, other serious skin disorders, pigmentation or extensive scarring in atopic dermatitis symptom region) 3. subjects who need prohibited medication during clinical period 4. pregnant, breast-feeding women or women who plan to become pregnant during this study 5. subjects who currently participate in other clinical trial or participated in other clinical trial within 4 weeks 6. any other condition which the investigator judges would make patient unsuitable for study participation

Keywords: atopic dermatitis stem cell cell therapy skin disease umbilical cord blood ucb-msc hucb-msc ad furestem dermatitis eczema
a safety and efficacy study of alphagan® p and lumigan® in subjects previously treated with latanoprost for glaucoma and ocular hypertension

Conditions: Glaucoma; Ocular Hypertension

Summary: this study will evaluate the efficacy and safety of either bimatoprost 0.01% ophthalmic solution (lumigan®) alone or bimatoprost 0.01% ophthalmic solution (lumigan®) and brimonidine tartrate 0.1% ophthalmic solution (alphagan® p) in combination in patients previously treated with latanoprost 0.005% ophthalmic solution monotherapy who require additional intraocular pressure (iop) lowering medication.


Eligibility criteria:
inclusion criteria: * ocular hypertension or glaucoma in at least 1 eye * visual acuity of 20/100 or better in both eyes exclusion criteria: * corneal refractive laser surgery (lasik, lasek, prk, rk) in the study eye(s) * intraocular or glaucoma surgery in the past 3 months
high flow nasal cannula in comparison to apneic oxygenation during foreign body removal by rigid bronchoscope

Conditions: Anesthesia

Summary: to compare the effect of hfnc with standard apneic oxygenation on patient oxygenation and airway protection during foreign body removal by rigid bronchoscope.

this study is a prospective, randomized controlled trial, at ain shams university hospitals, cardiovascular surgery hospital (thoracic surgery unit), cairo, egypt. we will include 64 patients planned for foreign body removal by rigid bronchoscope. all patients will be asa і with recent fb aspiration in the last 72hrs either by history or documented by radiopaque shadow in chest x ray or ct scan. after achievement of anesthesia and full muscle relaxation ventilation started by open mask technique. then the patients will be divided into two groups according to the oxygenation technique: group (a) (32 patients) hfnc (vapotherm) will be used during the bronchoscopy time flow rate 50 l/min with 100% humidified oxygen and the temperature adjusted to be 38℃ . group (b) (32 patients) (control group) using the standard apneic oxygenation through the side port of rigid bronchoscope during the procedure

Eligibility criteria:
inclusion criteria: * we will include 64 patients planned for foreign body removal by rigid bronchoscope. * all patients will be asa і * recent fb aspiration in the last 72hrs either by history or documented by radiopaque shadow in chest x ray or ct scan. exclusion criteria: * patients age not more than 40 years old. * body weight less than 40 kg. * critically ill patients. * intubated patients. * inhalation of fb more than 72 hrs.
caelyx biweekly in heavily pretreated patients with relapsed ovarian cancer

Conditions: Ovarian Cancer

Summary: effect of biweekly schedule of pld on dose-limiting toxicity of ppe and patient's quality of life

pegylated liposomal doxorubicin (pld) formulation has been approved for the treatment of recurrent ovarian cancer (roc). toxic skin reactions e.g. palmar-plantar erythrodysesthesia (ppe) were reported as being the dose-limiting toxicity and have an impact on patients' quality of life (qol). the primary aim of this study was to optimise the toxicity profile by choosing a biweekly schedule of pld furthermore, qol was investigated. secondary objective of this study was to evaluate the response rates of this new regimen.

Eligibility criteria:
inclusion criteria: * patients ≥ 18 years of age * recurrent ovarian, peritoneal, or tubal cancer and prior treatment with platinum- and paclitaxel were eligible to this trial. * eastern cooperative oncology group (ecog) performance status less than 3. * renal function (serum creatinine 1.25 times the upper limit of normal, glomerular filtration rate greater than 60 ml/min) * liver function (ast/ alt three times the upper limit of normal, bilirubin concentrations 1.25 the upper limit of normal) * bone marrow function (neutrophil count greater than 1.5 x 109/l, and a platelet count greater than 100 x 109/l). exclusion criteria: * patients with more than 4 chemotherapies in medical history * severe cardiac disease

Keywords: pegylated liposomal doxorubicin ppe ovarian cancer
effect of warm saline irrigation on bleeding in mandibular third molar surgery

Conditions: Surgical Blood Loss; Third Molar

Summary: the objective of this research is to compare the effect of irrigation during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° c and 37 ± 1 ° c for control and experimental sides, respectively.

the objective of this research is to compare the effect of irrigation during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° c and 37 ± 1 ° c for control and experimental sides, respectively. for this purpose, 40 mandibular impacted third molars will be randomly allocated to two groups and surgically removed with the abovementioned saline temperatures. finally, the suctioned liquids and duration of the surgeries will be carefully measured and compared between both sides.

Eligibility criteria:
inclusion criteria * being a candidate for bilateral mandibular third molar surgery * both mandibular third molars must have a similar inclination to the second molar * both mandibular third molars must have same pell \& gregory's classification exclusion criteria * presence of any systemic condition or using any type of medication * history of allergy to local anesthetic (la) solutions * patients with an active gag reflex * pregnant and post-menopause women * patients with pericoronitis or any local inflammation

Keywords: warm saline
late effects of proton radiation therapy in patients with low-grade glioma

Conditions: Low Grade Gliomas

Summary: in this research study, we are looking to study the side effects from the use of proton radiation in treating people with low-grade gliomas that are recommended radiation treatment. we expect response of the tumors to be the same with proton radiation as compared to standard 3d conformal radiation therapy, but also expect less side effects from radiation.

* participants will receive radiation therapy for 6 weeks, given in daily doses, monday through friday, for a total of 30 treatments. * a medical history and physical examination will be performed prior to the start of radiation treatment, weekly during the 6 weeks of radiation and after the finish of radiation performed at 3 and 6 months and then annually for 5 years. * hormonal function tests will be taken prior to the start of radiation treatment and after the finish of radiation treatment at 3 and 6 months, and annually for five years to assess the participants hormonal functions as they relate to the pituitary gland's function. * a brain mri will be performed prior to the start of radiation treatment and then performed at 3 and 6 months after radiation treatment then annually for 5 years. * a neurocognitive exam will be performed prior to the start of radiation therapy, a limited exam 6 months after the completion of radiation therapy, and a complete exam annually for 5 years. * quality of life and emotional well-being questionnaires will be done before radiation begins, 2 months after radiation treatment, 6 months after radiation treatment and then annually for 5 years.

Eligibility criteria:
inclusion criteria: * histologically confirmed low-grade gliomas, who classification ii/iv or equivalent low grade histology, including protoplasmic, fibrillary, gemistocytic astrocytomas, and mixed variants such as oligoastrocytomas * must have at least one of: (1) progressive or recurrent disease as defined by imaging, (2) persistence or progression of debilitating neurological symptoms, or (3) at risk of early progression as defined by either (a) age of 40 or older or (b) mib-1 of 3% or greater * kps of 70 or greater * 18 years of age or older * surgical and medical/chemotherapeutic interventions are per physician's discretion and are acceptable * must be able to speak and comprehend english exclusion criteria: * other baseline neurocognitive or emotional disorders or deficits, including but not limited to head injury, cva, tia, or other cerebral insults with residual neuropsychiatric deficits, psychiatric disorders, learning disabilities, hiv positivity or other medical conditions at high risk of causing neurocognitive decline or emotional instability * prior history of cranial irradiation * pregnancy at the time of radiation treatment * unable to undergo mri scans (e.g., embedded ferromagnetic metal or pacemakers) * comorbid illness or reason to suggest a life expectancy of less than 5 years

Keywords: proton radiation therapy photon radiation therapy
changes in inter-joint coordination and muscle activation after cruciate ligament injury of the knee joint

Conditions: To Investigate the Change of Inter-joint Coordination and Muscle Activation in Patients With Cruciate Ligament Injury During Stair Negotiation.

Summary: stair negotiation is an important activity of daily living. patients with cruciate ligament injury may have difficulty in stair negotiation because of the proprioception deficit and neuromuscular deficit caused by ligament injury. however, the influence of knee cruciate ligament injury on the control of movement is still unclear. since inter-joint coordination can provide the information of relationship between angle position and angle velocity, it may be useful to analysis the change of movement pattern.this current study aimed to investigate the change of inter-joint coordination and muscle activation in patients with cruciate ligament injury during stair negotiation.


Eligibility criteria:
inclusion criteria: * unilateral cruciate ligament injury or unilateral cruciate ligament reconstructed after 3 month * able to climb up and down with step-over-step pattern * bmi within 18 to 30 exclusion criteria: * complex ligament injury * lower limb fracture in recent years * meniscus injury * systematic disorder which would affect the balance and ambulation
impact and burden of postponing elective surgeries

Conditions: Mental Impairment; Complication

Summary: overall, little is known about the effects and burdens of postponed operations in patients with urological diseases. to investigate the consequences and develop possible strategies for overcoming these challenges, the investigators would like to evaluate the influence of operation shifts in more detail.

medical care in austria is struggling with staff shortages and consecutive or (operating room) closures. the current development seems to be the result of problems that have been postponed for a long time to be accelerated by the covid-19 pandemic. the introduction of covid-19 vaccination and the establishment of protective measures and handling standards with infected patients made it possible to return to the regular operation. however, there is currently no noticeable improvement in the overall situation. the increasing shortage of nursing care in austria is an increasingly urgent reason for this that affects all hospitals and care facilities. by prioritizing oncological interventions and an "oncology first" strategy at least oncological interventions and emergency interventions are performed on time. however, just looking at the waiting times for oncological interventions does not provide sufficient information of the current overall situation. the impairment for patients with non-oncological diseases have received little attention so far given. postponing elective surgery in patients with functional urological diseases (e.g. benign prostatic hyperplasia) can have a long-term impact on patient health and also means shifting their surgery burden and the stress for the patient. an american study observed a decrease in prostate cancer diagnoses and an increase in diagnostic delays and postponements of treatments due to the pandemic, which led to greater stress and uncertainty in the affected patients. the primary goal of this study is to record the burden on patients caused by the postponement of their surgery (mentally, physically). secondary outcomes include complication rates from postponement of surgery, effects on employment, awareness of the current situation (lack of care), state of health of patients upon admission to elective surgery.

Eligibility criteria:
inclusion criteria: - all patients over the age of 18 attending the department of urology for an elective surgery exclusion criteria: * lack of ability to give consent * emergency operations

Keywords: postponed surgery